Aerie Pharmaceuticals, a clinical-stage biotech developing treatments for glaucoma, raised $67 million by offering 6.7 million shares at $10, below the range of $12 to $14. Aerie Pharmaceuticals plans to list on the NASDAQ under the symbol AERI. Aerie Pharmaceuticals initially filed confidentially on 5/13/2013. RBC Capital Markets and Stifel acted as lead managers on the deal.
